KAHR develops innovative immuno-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack.
Location: Australia
Employees: 11-50
Total raised: $68.5M
Founded date: 2019
Investors 4
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| 03.08.2023 | Shavit Cap... | shavitcapi... |
| - | Myeloma In... | myelomainv... |
| - | Flerie Inv... | flerie.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.01.2026 | - | $22M | SPRIM Vent... |
| 16.06.2021 | - | $46.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 09.01.2026 | KAHR Bio: $22 Million Raised And Phase 2 Topline Data For DSP107 Combo In MSS Colorectal Cancer | KAHR Bio announced it posted “strong” topline results from a Phase 2a dose-expansion cohort evaluating its investigational immunotherapy DSP107 in combination with Roche’s atezolizumab (Tecentriq) in late-line metastatic microsatellite stab... |
| 17.11.2022 | Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma | MODI'IN, Israel, and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity to treat solid tumors a... |
| 16.06.2021 | KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline | - |
| 02.06.2021 | Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate | INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy co... |
| 25.02.2020 | Kahr raises $18M to test CD47 drug with Roche's Tecentriq | Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single agent and in combination with Roche’s ch... |
| 25.02.2020 | Kahr raises $18M to test CD47 drug with Roche's Tecentriq | Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single agent and in combination with Roche’s ch... |
| - | KAHR medical | “KAHR develops innovative immuno-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack.” |